focus -WSS

focus

author：hotspot 2025-09-30 22:09:16 - browse：3

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Merck drug for rare lung condition set for approval in U.S.

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Study says nonprofit hospitals fall short in charity care spending

Washington mulls new rules to avert another Change Healthcare

Argenx readies a blockbuster opportunity with drug for autoimmune disease

hotspot

focus

knowledge

In Memoriam: Notable people who died in 2023

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Peter Hotez and the public health issue of online harassment

Steward Health Care has deal to sell doctor network to UnitedHealth

In Memoriam: Notable people who died in 2023

Why the world’s most expensive drug might be worth the price

DIEP, the 'gold standard' of breast reconstruction, is under threat

Abortion pill Supreme Court ruling could impact entire drug industry

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Abortion pill Supreme Court ruling could impact entire drug industry

hotspot

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Merck drug for rare lung condition set for approval in U.S.

Virtual Event: March of the Biosimilars

The Readout: Lenmeldy, GLP

Virtual Event: March of the Biosimilars

States should stop sabotaging methadone treatment reform

knowledge

leisure time

hotspot

leisure time